← Back to Search

Monoclonal Antibodies

Depemokimab for Asthma

Phase 1
Waitlist Available
Research Sponsored by GlaxoSmithKline
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial tests Depemokimab given by a small syringe or autoinjector in healthy people to see how the body handles it, its safety, and if it causes any immune responses.

Who is the study for?
Healthy adults who weigh at least 50 kg with a BMI of 19-30 can join. They must have no significant allergies, especially to monoclonal antibodies or biologics, and no history of severe drug allergies or substance abuse. Women able to get pregnant should use effective birth control.
What is being tested?
The trial is testing Depemokimab delivered through two different devices: a Safety Syringe Device (SSD) and an autoinjector. It aims to compare how the body absorbs the drug, its safety, tolerability, and potential for immune response.
What are the potential side effects?
Possible side effects are not detailed but may include reactions typical for monoclonal antibody treatments such as injection site reactions, allergic responses, fatigue, headache, or flu-like symptoms.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Participants receiving depemokimab via an autoinjectorExperimental Treatment1 Intervention
Group II: Participants receiving depemokimab via a SSDExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Depemokimab
2022
Completed Phase 1
~140

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

PPD DEVELOPMENT, LPIndustry Sponsor
158 Previous Clinical Trials
35,909 Total Patients Enrolled
4 Trials studying Asthma
1,521 Patients Enrolled for Asthma
GlaxoSmithKlineLead Sponsor
4,805 Previous Clinical Trials
8,379,709 Total Patients Enrolled
301 Trials studying Asthma
500,482 Patients Enrolled for Asthma
PPDIndustry Sponsor
161 Previous Clinical Trials
36,251 Total Patients Enrolled
4 Trials studying Asthma
1,521 Patients Enrolled for Asthma

Media Library

Depemokimab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05602025 — Phase 1
Asthma Research Study Groups: Participants receiving depemokimab via a SSD, Participants receiving depemokimab via an autoinjector
Asthma Clinical Trial 2023: Depemokimab Highlights & Side Effects. Trial Name: NCT05602025 — Phase 1
Depemokimab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05602025 — Phase 1
Asthma Patient Testimony for trial: Trial Name: NCT05602025 — Phase 1
~48 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top